MK-7243 yielded improvements vs placebo of 23 % in entire-season TCS ( median difference-0 .98 , P < .001 ) , 29 % in peak-season TCS ( median difference-1 .33 , P < .001 ) , 20 % in entire-season DSS ( median difference-0 .64 , P = .001 ) , 35 % in entire-season DMS ( mean difference-0 .48 , P < .001 ) , and 12 % in peak-season rhinoconjunctivitis quality-of-life questionnaire ( median difference-0 .13 , P = .027 ) .